Omeros (OMER) Total Current Liabilities (2010 - 2026)
Omeros (OMER) posted Total Current Liabilities of $59.4 million for Q1 2026, down 23.85% sequentially from $78.1 million in Q4 2025, and down 28.57% YoY from $83.2 million in Q1 2025.
Omeros (OMER) Total Current Liabilities (2010 - 2026) Analysis & Trends
Omeros has reported Total Current Liabilities for 17 years, with the latest figure at $59.4 million in Q1 2026.
- Quarterly Total Current Liabilities fell 28.57% year-over-year to $59.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.4 million (down 28.57% YoY) and the FY2025 annual result came in at $78.1 million, down 1.84% from the prior year.
- Total Current Liabilities slipped to $59.4 million in Q1 2026 per OMER's latest filing, from $78.1 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $147.2 million in Q3 2023 and troughed at $35.1 million in Q1 2022.
- A 5-year average of $80.8 million and a median of $78.1 million in 2025 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Current Liabilities soared 296.94% in 2023, then slumped 62.21% in 2024.
- Over 5 years, Total Current Liabilities stood at $136.4 million in 2022, then tumbled by 60.91% to $53.3 million in 2023, then surged by 49.16% to $79.5 million in 2024, then slipped by 1.84% to $78.1 million in 2025, then retreated by 23.85% to $59.4 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $59.4 million, $78.1 million, and $80.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn | 94.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 94.96 Mn |
| Mar 31, 2026 | 59.44 Mn |
| Dec 31, 2025 | 78.06 Mn |
| Sep 30, 2025 | 80.76 Mn |
| Jun 30, 2025 | 85.50 Mn |
| Mar 31, 2025 | 83.22 Mn |
| Dec 31, 2024 | 79.53 Mn |
| Sep 30, 2024 | 55.62 Mn |
| Jun 30, 2024 | 59.48 Mn |
| Mar 31, 2024 | 59.06 Mn |
| Dec 31, 2023 | 53.32 Mn |
| Sep 30, 2023 | 147.18 Mn |
| Jun 30, 2023 | 143.54 Mn |
| Mar 31, 2023 | 139.19 Mn |
| Dec 31, 2022 | 136.38 Mn |
| Sep 30, 2022 | 39.51 Mn |
| Jun 30, 2022 | 38.50 Mn |
| Mar 31, 2022 | 35.07 Mn |
| Dec 31, 2021 | 51.79 Mn |
| Sep 30, 2021 | 42.82 Mn |